Acrivon Therapeutics, Inc.

ACRV Nasdaq SEC CIK 1781174
Follow Acrivon Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$17.9M +1.8% vs same quarter last year
EPS, diluted −$0.42 +10.6% vs same quarter last year
Operating cash flow −$12.4M −0.8% vs same quarter last year
Operating income −$18.5M +5.9% vs same quarter last year
Net income by quarter
−$22.8M
−$19.7M
−$21M
−$18.2M
−$19M
−$19M
−$18M
−$17.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$100M−$75M−$50M−$25M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$77.9M
FY24−$80.6M
FY23−$60.4M
FY22−$31.2M
FY21−$16.2M
FY20-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$65.3M
FY24−$68.4M
FY23−$43.9M
FY22−$32.3M
FY21−$14.2M
FY20-